Literature DB >> 16942662

Diagnostic and treatment modalities for autoimmune pancreatitis.

Atul S Rao1, Francesco Palazzo, Joanne Chung, Eric Hager, Hamid Abdollahi, Charles J Yeo.   

Abstract

Since the recognition of autoimmune pancreatitis (AIP) as a clinical entity, many advances have been made in defining clinical, radiologic, histologic, and laboratory parameters to assist in a complete definition of the disease. Despite all these efforts, a preoperative diagnosis still remains a clinical challenge but is of paramount importance, as these cases have been reported to be steroid-responsive; therefore, early treatment may obviate the need for surgical resection. Although the utilization of recently proposed guidelines by the Japanese Pancreas Society and an Italian study group may further assist the clinician and prompt the initiation of steroid treatment, the response to therapy should be observed within 2 to 4 weeks and reflected in progressive resolution of the presenting radiologic and laboratory abnormalities. Should these fail to demonstrate improvement, the diagnosis of AIP should undergo re-evaluation, and consideration for surgical exploration should be made, as the patient may be harboring a malignancy. Surgical resection in the form of pylorus-preserving pancreaticoduodenectomy remains the optimal solution in the attempt to clarify the diagnosis and offer treatment with low complication rates.

Entities:  

Year:  2006        PMID: 16942662     DOI: 10.1007/BF02738526

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  36 in total

Review 1.  Autoimmune related pancreatitis.

Authors:  K Okazaki; T Chiba
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

2.  Response to steroid therapy of sclerosing cholangitis after duodenopancreatectomy due to autoimmune pancreatitis.

Authors:  D Padilla; T Cubo; P Villarejo; R Pardo; A Jara; R de la Plaza; J Hernández
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

3.  High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Authors:  H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

4.  Non-alcoholic duct destructive chronic pancreatitis.

Authors:  N Ectors; B Maillet; R Aerts; K Geboes; A Donner; F Borchard; P Lankisch; M Stolte; J Lüttges; B Kremer; G Klöppel
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

5.  Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas.

Authors:  K Kawaguchi; M Koike; K Tsuruta; A Okamoto; I Tabata; N Fujita
Journal:  Hum Pathol       Date:  1991-04       Impact factor: 3.466

Review 6.  Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis.

Authors:  K Yoshida; F Toki; T Takeuchi; S Watanabe; K Shiratori; N Hayashi
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

7.  Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases.

Authors:  Kenji Notohara; Lawrence J Burgart; Dhiraj Yadav; Suresh Chari; Thomas C Smyrk
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

Review 8.  Autoimmune pancreatitis: pathological, clinical, and immunological features.

Authors:  Günter Klöppel; Jutta Lüttges; Matthias Löhr; Giuseppe Zamboni; Daniel Longnecker
Journal:  Pancreas       Date:  2003-07       Impact factor: 3.327

Review 9.  Pancreatic pseudotumor with sclerosing pancreato-cholangitis: is this a systemic disease?

Authors:  Mohssen Nassiri Toosi; Jenny Heathcote
Journal:  Am J Gastroenterol       Date:  2004-02       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.